Burt Adelman has been appointed executive vice president, research and development at Biogen (Cambridge, MA). Dr. Adelman joined Biogen in 1991 as director of medical research, and has held positions of increasing responsibility including vice president, development operations, and vice president, regulatory affairs. He was most recently vice president of medical research.

PTC Therapeutics (South Plainfield, NJ) has appointed John Babiak as senior vice president of drug discovery technologies. Dr. Babiak was most recently at Pharmacopeia, where he served as vice president of technology, responsible for HTS technologies, research engineering, analytical chemistry, ADME, and software development.

Kenneth Boger has been appointed to the newly created position of senior vice president and general counsel at Vertex Pharmaceuticals (Cambridge, MA). He joins the company from the law firm Kirkpatrick & Lockhart, where he served on its management committee.

Keryx Biopharmaceuticals (Cambridge, MA) has appointed Barry Cohen to the position of vice president, business development. Mr. Cohen joins Keryx from Novartis Consumer Health, where he was vice president. Keryx also named Rony Seger, an associate professor in the department of biological regulation at the Weizmann Institute of Science, as its chief scientific officer.

Domenico Criscuolo has been appointed director of clinical development at Novuspharma (Monza, Italy). Dr. Criscuolo will oversee development of Novuspharma's clinical programs, including preregistration studies with BBR 2778, the company's lead product for non-Hodgkin's lymphoma, which is expected to enter phase III studies in the coming months. Most recently, he was head of clinical research and drug safety at Roche in Milan.

Xcyte Therapies (Seattle, WA) has appointed Mark Frohlich as medical director. Dr. Frohlich, a medical oncologist, is an assistant adjunct professor of medicine at the University of California, San Francisco.

Michael Furlong has been named senior director, business development of Phylos (Lexington, MA). Previously, he was vice president, business development at Mosaic Technologies.

SuperGen (Dublin, CA) has announced that Edward L. Jacobs, who served as executive vice president, commercial operations from 1999–2001, has rejoined the company in an expanded role, as chief business officer and chief financial officer. Earlier this year, Mr. Jacobs left SuperGen to assume the position of president and CEO of ETEX Corp., a biomaterials and drug delivery company. While at ETEX, Mr. Jacobs restructured the company and orchestrated its sale, pending approval from ETEX's board, to a major multinational health care company.

StemCells, Inc. (Palo Alto, CA) has announced that Ricardo B. Levy has joined its board of directors. Dr. Levy is chairman of the board of Catalytica Energy Systems, and is a founder and former president and CEO of Catalytica, Inc.

J. Misha Petkevich has been elected to the board of directors of Incara Pharmaceuticals (Research Triangle Park, NC). Mr. Petkevich is founder, chairman, and CEO of the investment banking firm Petkevich & Partners, and was previously managing director and head of investment banking at BancAmerica Robertson Stephens.

Zahed Subhan has been appointed to the position of senior vice president and head of business development at Genmab (Copenhagen, Denmark). Dr. Subhan joins Genmab from Gemini Genomics, where he was executive vice president of business development.

GeneProt (North Brunswick, NJ) has named Ranald Sutherland vice president, business development. Most recently, he held the same position at F. Hoffmann-La Roche in Germany.

Nature Biotechnology offers its sympathies and condolences to those affected by the recent tragedies in New York City, Washington, DC, and southwestern Pennsylvania, and especially to the friends and families of Thomas E. Burnett Jr., senior vice president and chief operating officer of Thoratec (Pleasanton, CA), Dora Menchaca, associate director of clinical research at Amgen (Thousand Oaks, CA), Lisa Raines, senior vice president of governmental relations at Genzyme (Cambridge, MA), and Klaus J. Sprockamp, CFO of LION Bioscience (Heidelberg, Germany).